The Horizon programme contains a variety of mRNA assets in varying stages of development, including a preclinical in vivo candidate.

Lipid nanoparticle (LNP) delivery of RNA therapeutics is constrained by poor tissue selectivity and off-target toxicity. Most high-throughput screening approaches have focused on single-target ...